Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Retained Earnings (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Retained Earnings for 2 consecutive years, with -$443.2 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 260805.88% to -$443.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$443.2 million through Dec 2025, down 260805.88% year-over-year, with the annual reading at -$443.2 million for FY2025, 260805.88% down from the prior year.
  • Retained Earnings for Q4 2025 was -$443.2 million at Pyxis Oncology, down from -$425.1 million in the prior quarter.
  • The five-year high for Retained Earnings was $170000.0 in Q4 2024, with the low at -$443.2 million in Q4 2025.